Back to the real world in NYC; time to get a real
Post# of 151628
(Total Views: 755)
Posted On: 07/22/2022 11:39:35 PM
Back to the real world in NYC; time to get a real therapeutic against Covid going:
The study, published in the "Nature" journal on Tuesday, says BA.5 and BA.4 (15.2% of NYS cases on top of the estimated 40% associated with BA.5), are 4.2 times more vaccine-resistant than BA.2. Researchers said subvariant BA.2.12.1, which fueled the May case and hospitalization surge that sent 87% of all New York state counties into COVID high risk, according to the CDC, was found to be only 1.8 times more resistant.
According to the study, mutation at a key protein spike residue found in BA.5, BA.4 and BA.2.12.1 facilitates escape from some antibodies. The first two subvariants do have a mutation that compromises that ability to escape, but a reversion mutation "restores receptor affinity and consequently the fitness of BA.4/5," it says. Just one therapeutic antibody authorized for clinical use retains full potency against them, it adds.
We start the deaths again soon.
The study, published in the "Nature" journal on Tuesday, says BA.5 and BA.4 (15.2% of NYS cases on top of the estimated 40% associated with BA.5), are 4.2 times more vaccine-resistant than BA.2. Researchers said subvariant BA.2.12.1, which fueled the May case and hospitalization surge that sent 87% of all New York state counties into COVID high risk, according to the CDC, was found to be only 1.8 times more resistant.
According to the study, mutation at a key protein spike residue found in BA.5, BA.4 and BA.2.12.1 facilitates escape from some antibodies. The first two subvariants do have a mutation that compromises that ability to escape, but a reversion mutation "restores receptor affinity and consequently the fitness of BA.4/5," it says. Just one therapeutic antibody authorized for clinical use retains full potency against them, it adds.
We start the deaths again soon.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼